Letrovena

Letrozole, the active ingredient in Letrovena, is an aromatase inhibitor presented as an oral tablet for postmenopausal breast cancer treatment. It works by selectively blocking the aromatase enzyme, reducing estrogen production, which helps to slow the growth of hormone‑receptor‑positive tumors in postmenopausal women. The medication is indicated for use after surgery or as part of adjuvant therapy, and may be combined with other endocrine agents under medical supervision.

GNH USA supplies Letrovena as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and pharmacies worldwide.

Letrozole is used in the endocrine therapy of hormone‑receptor‑positive breast cancer, primarily in postmenopausal patients. - Postmenopausal hormone‑receptor‑positive breast cancer: reduces tumor recurrence and progression when used as adjuvant or first‑line endocrine therapy. - Advanced or metastatic breast cancer: provides disease control in patients whose disease has progressed on prior hormonal therapy. - Neoadjuvant setting before surgery: lowers tumor size to facilitate breast‑conserving surgery.

Letrozole may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Hot flashes: transient episodes of increased skin temperature and sweating. - Joint or muscle pain: arthralgia or myalgia affecting daily activities. - Fatigue: persistent tiredness not relieved by rest.

Serious or Rare Side Effects: - Severe bone loss: increased risk of osteoporosis and fractures. - Cardiovascular events: thromboembolism or myocardial infarction. - Liver dysfunction: elevated transaminases or hepatitis.

When prescribing Letrovena, clinicians should observe several precautionary measures to ensure patient safety. - Assess bone mineral density: baseline DEXA scan recommended before initiating therapy. - Monitor lipid profile: estrogen suppression may alter cholesterol levels. - Evaluate hepatic function: adjust use in patients with liver impairment. - Avoid use in pregnancy: Letrozole is contraindicated in pregnant women (Category X). - Store at ambient temperature: keep below 25°C in original container, protect from moisture and light.

Letrozole can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may markedly reduce letrozole plasma levels. - Tamoxifen: concurrent use may antagonize therapeutic effect.

Moderate Interactions (Monitor Closely): - Anticoagulants (warfarin): increased risk of bleeding, monitor INR. - Selective serotonin reuptake inhibitors (SSRIs): may exacerbate hot flashes. - Cholesterol‑lowering agents (statins): potential for altered lipid changes; monitor lipid profile.